Aldastotug

{
  "id": "MLC-T-ONC-009758",
  "term": "Aldastotug",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody targeting the immune checkpoint molecule sialic acid-binding immunoglobulin (Ig)-like lectin 15 (Siglec-15; SIGLEC15; S15; CD33L3), with potential immune checkpoint inhibitory, antineoplastic and immunomodulatory activities. Upon administration, aldastotug targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells and inhibition of CD8-positive and CD4-positive T-cell responses. This leads to activation of the immune system and an inhibition of tumor cell growth. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, is overexpressed on and may play a key role in the survival and differentiation of TAMs and various tumor cells.",
  "synonyms": [
    "anti-S15 monoclonal antibody PYX-106",
    "anti-Siglec-15 monoclonal antibody BSI-060T",
    "anti-Siglec-15 monoclonal antibody PYX-106"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/aldastotug/"
}